What question did this study set out to answer?

This research aims to compare the effectiveness of mesenchymal stem cells derived from different sources in treating acute graft-versus-host disease.

A Comparative Study of Mesenchymal Stem Cell Derived From Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Through a Trophoblast-like Stage and Bone Marrow-derived Mesenchymal Stem Cells in Treating Acute Xenogeneic Graft-versus-host Disease in Humanized Mice

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates T-MSCs and BM-MSCs for alleviating aGvHD in humanized mice, suggesting potential clinical applications.

This research aims to compare the effectiveness of mesenchymal stem cells derived from different sources in treating acute graft-versus-host disease.
Investigated T-MSCs from trophoblasts and BM-MSCs from bone marrow in humanized NPG mice.
Evaluated clinical scores and pathological damage, using flow cytometry and cytokine assays.
Probed mechanisms of MSC efficacy with inhibitors and blocking antibodies.
T-MSCs (3 × 105 cells/mouse) and BM-MSCs (3 × 105 cells/mouse) significantly reduced aGvHD severity after a single dose (p<0.05).
Both MSC types inhibited CD4+ and CD8+ T-cell proliferation, regulated by prostaglandin E2.
CD3+CD25high+Foxp3+ T cells increased with both MSC treatments, indicating enhanced regulatory T-cell activity.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark